Long-term therapy to prevent stroke

被引:14
作者
Kirshner, HS
Biller, J
Callahan, AS
机构
[1] Vanderbilt Univ, Sch Med, Dept Neurol, Med Ctr, Nashville, TN 37212 USA
[2] Loyola Univ Chicago, Stritch Sch Med, Dept Neurol, Maywood, IL USA
[3] Neurol Consultants PC, Nashville, TN USA
来源
JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE | 2005年 / 18卷 / 06期
关键词
D O I
10.3122/jabfm.18.6.528
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cerebrovascular disease is the third leading cause of mortality and the leading cause of long-term neurological disability in the United States. Most strokes are of ischemic origin and, other than cardioembolic or small vessel strokes, are caused by the development of platelet-fibrin thrombi on an atherosclerotic plaque. This underlying disease mechanism shares important features with coronary artery disease and peripheral artery disease, highlighting the systemic nature of atherothrombosis and the elevated cross risk in stroke patients for ischemic events in other vascular beds. It has been estimated that up to 80% of ischemic strokes could be prevented with application of currently available treatments for blood pressure, cholesterol, and antithrombotic therapies. Stroke is not, like cancer, waiting for a scientific breakthrough; stroke preventive treatments are well understood and widely available. It is only the application of these treatments to patients, many of whom do not visit physicians, that is lacking. Clearly, better education of the public and active participation of primary care physicians is essential to get the message out to all those at risk.
引用
收藏
页码:528 / 540
页数:13
相关论文
共 74 条
[1]   Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke - A scientific statement for healthcare professionals from the stroke council and the council on clinical cardiology of the American Heart Association/American Stroke Association [J].
Adams, RJ ;
Chimowitz, MI ;
Alpert, JS ;
Awad, IA ;
Cerqueria, MD ;
Fayad, P ;
Taubert, KA .
STROKE, 2003, 34 (09) :2310-2322
[2]  
*AHA ASA, 2002, STROKE, V35, P1023
[3]   Antithrombotic and thrombolytic therapy for ischemic stroke [J].
Albers, GW ;
Amarenco, P ;
Easton, JD ;
Sacco, RL ;
Teal, P .
CHEST, 2004, 126 (03) :483S-512S
[4]  
Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[5]  
Albers GW, 2003, LANCET, V362, P1691
[6]   Risk reduction strategies in ischaemic stroke - The role of antiplatelet therapy [J].
Alberts, MJ ;
Atkinson, R .
CLINICAL DRUG INVESTIGATION, 2004, 24 (05) :245-254
[7]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[8]   Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? [J].
Amarenco, P ;
Donnan, GA .
STROKE, 2004, 35 (11) :2606-2608
[9]  
[Anonymous], 2004, HEART DIS STROK STAT
[10]   Acute stroke care in the US - Results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry [J].
Arora, S ;
Broderick, JP ;
Frankel, M ;
Heinrich, JP ;
Hickenbottom, S ;
Karp, H ;
LaBresh, KA ;
Malarcher, A ;
Mensah, G ;
Moomaw, CJ ;
Reeves, MJ ;
Schwamm, L ;
Weiss, P .
STROKE, 2005, 36 (06) :1232-1240